I really do think its a game changer
FDA Oversight: 503A vs 503B Federal oversight of compounding pharmacies falls under two distinct categories established by the Drug Quality and Security Act of 2013
Hepatic Steatosis : Recently, a sub-study of the phase 3 clinical trial SURPASS-3 showed that, among patients receiving metformin and/or SGLT2 inhibitors, the addition of tirzepatide (10 or 15 mg) as compared to insulin degludec was able to significantly reduce hepatic fat content (evaluated by magnetic resonance) after 52 weeks of treatment
Rare but Serious Risks Serious complications associated with semaglutide are uncommon, particularly when treatment is medically supervised
Antiemetic medication can be used to counter the nausea if it is severe or there is vomiting but antiemetic medication should only be used if necessary and should not be used on a continual basis
However, in the SURMOUNT 3 trial involving adults without T2D, tirzepatide-treated females were significantly more likely to achieve a body weight reduction of at least 5% and 10% than tirzepatide-treated males
